Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection

Journal of Infectious Diseases

Volumn 183, Issue 3, 2001, Pages 401-408

  Call, Stephanie A ^a,d   Saag, Michael S ^a   Westfall, Andrew O ^a   Raper, James L ^a   Pham, Sissi V ^b   Tolson, Jerry M ^b   Hellmann, Nicholas S ^c   Cloud, Gretchen A ^a   Johnson, Victoria A ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ARTICLE; DRUG SENSITIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS INHIBITION; VIRUS LOAD; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 0035253297     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/318078     Document Type: Article

References (33)

1. Update: Trends in AIDS incidence - United States, 1996
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
3. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
4. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
6. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
7. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
8. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir
9. Impact of drug resistance mutations on virologic response to salvage therapy
10. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
11. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
12. Antiretroviraldrug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society - USA Panel
13. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
14. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
15. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type I protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
16. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
17. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
18. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: Association with therapy failure
19. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
20. Validation of the performance characteristics of a novel, rapid phenotypic drug susceptibility assay, PhenoSense HIV
21. Nonparametric estimation from incomplete observations
22. Regression models and life-tables
23. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
24. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel
25. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
26. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy
27. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type I isolates from patients with combination antiretroviral therapy failure
28. Use of changes in plasma levels of human immunodeficiency virus type I RNA to assess the clinical benefit of antiretroviral therapy
29. Clinical trials using HIV-1 RNA-based primary endpoints: Statistical analysis and potential biases
30. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals
31. +T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection